Risk of venous thromboembolism with the use of oral contraceptives
Sübutlu məlumatların xülasələri
10.05.2016 • Sonuncu dəyişiklik 10.05.2016
Editors
An association between oral contraceptive use and venous thromboembolism (VTE) appears to exist, but the reported risk is probably exaggerated. The users of non-third-generation OCs have a less than 3-fold increase in risk for VTE compared to nonusers: the risk for VTE is possibly higher in users of third-generation OCs.
A systematic review , abstracted in DARE, assessed the risk of nonfatal venous thromboembolism (VTE) with oral contraceptive use (OC) (13 case-control studies, 3 retrospective cohort studies, 5 prospective cohort studies, and 1 RCT) and fatal VTE with OC use (2 case-control studies, 2 prospective cohort studies, 1 RCT). The pooled risk ratio for OC was 3.0 (95% CI 2.6 to 3.4) in case-control studies, 4.8 for retrospective cohort studies, 2.4 in prospective cohort studies, and 1.1 in RCTs. In users or third-generation OCs, the
pooled risk ratio for VTE was 5.0 (95% CI 2.5 to 7.5).
Comment: The quality of evidence is upgraded by large magnitude of effect.
Ədəbiyyat
- Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997 Jul 28;157(14):1522-30.